BERGEN, Norway, July 7, 2020 /PRNewswire/ -- BerGenBio ASA (OSE:
BGBIO), a clinical-stage biopharmaceutical company developing
novel, selective AXL kinase inhibitors for severe unmet medical
need, announces that Dr. Akil
Jackson, Medical Director at BerGenBio, will be
participating at the Sachs Associates Digital Novel Coronavirus
Investment Forum on 8-9 July 2020.
Dr. Jackson will participate in a panel discussion entitled:
The Potential Therapeutic Strategies to Prevent and Conquer
Covid-19, on 8 July at 4:15pm
CEST. Dr. Jackson will also deliver a presentation on
BerGenBio at 11:35am CEST on 9
July.
The presentation will be made available on the Company website
on 9 July: www.bergenbio.com/investors/presentations/.
Further details on the Sachs Associates Digital Novel
Coronavirus Investment Forum can be found here.
About AXL
AXL kinase is a cell membrane receptor and an essential mediator
of the biological mechanisms underlying life-threatening diseases.
In cancer, AXL suppresses the body's immune response to tumours and
drives cancer treatment failure across many indications. AXL
expression defines a very poor prognosis subgroup in most cancers.
AXL inhibitors, therefore, have potential high value at the centre
of cancer combination therapy, addressing significant unmet medical
needs and multiple high-value market opportunities. Research has
also shown that AXL mediates other aggressive diseases.
About Bemcentinib
Bemcentinib (formerly known as BGB324), is a potentially
first-in-class selective AXL inhibitor in a broad phase II clinical
development programme. Ongoing clinical trials are investigating
bemcentinib in multiple solid and haematological tumours, in
combination with current and emerging therapies (including
immunotherapies, targeted therapies and chemotherapy), and as a
single agent. Bemcentinib targets and binds to the intracellular
catalytic kinase domain of AXL receptor tyrosine kinase and
inhibits its activity. Increase in AXL function has been linked to
key mechanisms of drug resistance and immune escape by tumour
cells, leading to aggressive metastatic cancers.
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused
on developing transformative drugs targeting AXL as a potential
cornerstone of therapy for aggressive diseases, including
immune-evasive, therapy resistant cancers. The company's
proprietary lead candidate, bemcentinib, is a potentially
first-in-class selective AXL inhibitor in a broad phase II oncology
clinical development programme focused on combination and single
agent therapy in lung cancer, leukaemia and COVID-19. A
first-in-class functional blocking anti-AXL antibody, tilvestamab,
is undergoing phase I clinical testing. In parallel, BerGenBio is
developing companion diagnostic tests to identify patient
populations most likely to benefit from bemcentinib: this is
expected to facilitate more efficient registration trials
supporting a precision medicine-based commercialisation
strategy.
BerGenBio is based in Bergen,
Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo
Stock Exchange (ticker: BGBIO). For more information,
visit www.bergenbio.com
Forward looking statements
This announcement may contain forward-looking statements, which
as such are not historical facts, but are based upon various
assumptions, many of which are based, in turn, upon further
assumptions. These assumptions are inherently subject to
significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and
other important factors could cause actual events to differ
materially from the expectations expressed or implied in this
announcement by such forward-looking statements.
This information is subject to the disclosure requirements
pursuant to section 5-12 of the Norwegian Securities Trading
Act.
For more information, please contact:
Richard Godfrey
CEO, BerGenBio ASA
+47-917-86-304
Rune Skeie
CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47-917-86-513
International Media Relations
Mary-Jane Elliott, Chris
Welsh, Lucy Featherstone,
Carina Jurs
Consilium Strategic Communications
bergenbio@consilium-comms.com
+44-20-3709-5700
Media Relations in Norway
Jan
Petter Stiff
Crux Advisers
stiff@crux.no
+47-995-13-891
This information was brought to you by Cision
http://news.cision.com
The following files are available for download:
https://mb.cision.com/Main/15728/3149808/1275735.pdf
|
Release
|